Systematic review on Parkinson's disease treated with pramipexole / 中华神经科杂志

ABSTRACT

Objective To systemically evaluate the therapeutic effect of pramipexole in treating Parkinson's disease. Methods Pubmed, Embase, Cochrane Database were used to search for randomized control trials (RCTs) on Parkinson's disease treated with pramipexole. Meticulous data wre extracted and meta-analysis was performed according to a preset protocol. Results Ten RCTs involving 1738 patients were included. The results of meta-analysis showed that pramipexole decreased the total scores of unified Parkinson's disease rating scale [UPDRS, WMD=-10.01,95%CI (-12.76,-7.26)],UPDRS part [WMD=-2.44,95%CI(-2.93,-1.95)],and UPDRS partⅢ[WMD=-6.61,95%CI(-8.38,-4.84)]. Pramipexole also reduced the score of UPDRS part Ⅳ[WMD=-0.73,95%CI(-1.16,-0.30)] in advanced patients(P＜0.05＝.Three studies referred to the effect of pramipexole in treating parkinsonian tremor. However there was a clinical heterogeneity among the studies, and two of them revealed a significant difference. Conclusions Pramipexole might improve motor symptoms and the quality of life in advanced patients, as well as improve tremor, which needs more RCTs to be confirmed.